On April 30, 2014, the United States Food and Drug Administration approved umeclidinium (brand name: Incruse Ellipta) as a once-daily inhaled bronchodilator for treatment of those with COPD, including chronic bronchitis and emphysema. As of January 2015, this medication is available in US pharmacies.
Incruse Ellipta is in the class of bronchodilators called long-acting muscarinic antagonists (LAMA). Other approved medications in this class are tiotropium (brand name: Spiriva HandiHaler and Respimat) and aclidinium (brand name: Tudorza Pressair). These medications open the airways and make it easier to breathe by blocking a receptor in the muscles that wrap around breathing tubes.
Incruse Ellipta is a once-daily dry powder bronchodilator
Spiriva Respimat is a once daily bronchodilator that delivers a mist
Information about the bronchodilator (called the package insert) states that Incruse Ellipta should be used with caution in those with narrow-angle glaucoma and with urinary retention due to enlargement of the prostate. The most common reported side effect in studies was nasopharyngitis (irritation of nose and throat). Also, you should not take this medication if you are using Spiriva or Tudorza as they are the same type of brocnhodilators.
Tudorza Pressair is a twice daily dry powder bronchodilator
As always, you should discuss any new medication with your doctor.